Blog

Cody Shandraw Invests in Entrepreneurs Obsessed with Impacting and Improving Lives – Psychedelic Investors #1

Aug 3 • 1 min read

With season one of the Psychedelic Invest Podcast in the books, season two is right around the corner. Since there are so many amazing people in this industry making an impact, though, we couldn’t wait to publish more content. That’s why we’re releasing a subseries for the podcast called “Psychedelic Investors.” This miniseries will feature…

Kaya Holdings to Seek Licenses for First Ever State Legal Psilocybin Manufacturing and Facilitation Service Centers in Oregon

Aug 3 • 4 min read

Kaya Holdings, Inc. (OTCQB: KAYS), the first U.S. publicly traded company to hold and operate cannabis licenses in all “touch the plant” categories, announced today that it has initiated the process to seek the requisite licenses for psilocybin manufacturing and facilitation service centers in Oregon. In November 2020 Oregon became the first state in the…

Many Counties Are Voting To Opt Out – But That Doesn’t Mean The End Of Measure 109

Aug 2 • 6 min read

If you were to just look at the map below, you’ll quickly grow concerned and confused about the future of Measure 109 in Oregon. After all, didn’t the state vote “Yes?” The map is a bit deceptive, though. A little bit of research has excavated the many reasons psychedelic supporters need not be concerned… yet….

COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference

Aug 2 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming events as follows: BTIG Biotechnology Conference: host investor meetings on 9 August 2022 Canaccord Annual Growth Conference: presentation at 8:30 am ET on 10 August…

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

Aug 2 • 2 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022. A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video interview will…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546